Literature DB >> 8527539

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.

R A Kuschner1, A F Trofa, R J Thomas, C W Hoge, C Pitarangsi, S Amato, R P Olafson, P Echeverria, J C Sadoff, D N Taylor.   

Abstract

We evaluated the use of azithromycin (500 mg) or ciprofloxacin (500 mg) daily for 3 days for the treatment of acute diarrhea among United States military personnel in Thailand. Stool cultures were obtained and symptoms were recorded on study days 0, 1, 2, 3, and 10. Campylobacter species were the most common pathogen isolated (44 isolates from 42 patients). All Campylobacter isolates were susceptible to azithromycin; 22 were resistant to ciprofloxacin. Among the 42 patients with campylobacter infection, there were 2 clinical and 6 bacteriologic treatment failures in the ciprofloxacin group and no treatment failures in the azithromycin group (P = .021 for bacteriologic failures). Overall, azithromycin was as effective as ciprofloxacin in decreasing the duration of illness (36.9 hours vs. 38.2 hours, respectively) and the number of stools (6.4 vs. 7.8, respectively). Among those not infected with Campylobacter species (n = 30), the duration of illness was 32.9 hours vs. 20.7 hours (P = .03) for the azithromycin and ciprofloxacin groups, respectively. Azithromycin is superior to ciprofloxacin in decreasing the excretion of Campylobacter species and as effective as ciprofloxacin in shortening the duration of illness. Azithromycin therapy may be an effective alternative to ciprofloxacin therapy in areas where ciprofloxacin-resistant Campylobacter species are prevalent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527539     DOI: 10.1093/clinids/21.3.536

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

Review 1.  Preparing patients to travel abroad safely. Part 4: Reducing risk of accidents, diarrhea, and sexually transmitted diseases.

Authors:  R E Thomas
Journal:  Can Fam Physician       Date:  2000-08       Impact factor: 3.275

2.  Antibiotics for Travelers: What's Good and What's Not.

Authors:  Kathryn N. Suh; Jay S. Keystone
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 3.  Prevention and self-treatment of traveler's diarrhea.

Authors:  David J Diemert
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 4.  [Treating travelers' diarrhea. When should medication be given?].

Authors:  G Birkenfeld
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

5.  New World monkey Aotus nancymae as a model for Campylobacter jejuni infection and immunity.

Authors:  Franca R Jones; Shahida Baqar; Alfonso Gozalo; Gladys Nunez; Nereyda Espinoza; Sharina M Reyes; Milagros Salazar; Rina Meza; Chad K Porter; Stephen E Walz
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Infection with ciprofloxacin-resistant Campylobacter jejuni in travellers returning from Asia.

Authors:  M A Slavin; I Jennens; W Tee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

7.  Travellers' diarrhea in children.

Authors:  Pierre J Plourde
Journal:  Paediatr Child Health       Date:  2003-02       Impact factor: 2.253

Review 8.  Diagnosis and treatment of bacterial diarrhea.

Authors:  James V Lawler; Mark R Wallace
Journal:  Curr Gastroenterol Rep       Date:  2003-08

9.  Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.

Authors:  J Engberg; F M Aarestrup; D E Taylor; P Gerner-Smidt; I Nachamkin
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

10.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.